Tilray Inc (NASDAQ:TLRY – Get Free Report) was up 1.5% on Thursday . The company traded as high as $1.70 and last traded at $1.69. Approximately 4,121,345 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 25,267,654 shares. The stock had previously closed at $1.66.
Tilray Trading Up 1.5 %
The firm has a market capitalization of $1.30 billion, a PE ratio of -3.83 and a beta of 2.19. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.27 and a quick ratio of 1.42. The company has a fifty day moving average of $1.82 and a 200-day moving average of $1.88.
Tilray (NASDAQ:TLRY – Get Free Report) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $229.90 million for the quarter, compared to analysts’ expectations of $226.20 million. Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same period last year, the business earned ($0.15) earnings per share. On average, sell-side analysts anticipate that Tilray Inc will post -0.12 earnings per share for the current fiscal year.
Institutional Trading of Tilray
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Further Reading
- Five stocks we like better than Tilray
- Roth IRA Calculator: Calculate Your Potential Returns
- Emerging Markets: What They Are and Why They Matter
- Manufacturing Stocks Investing
- Recession or Not, These 3 Stocks Are Winners
- What is Put Option Volume?
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.